Plaintiff
1 case as plaintiff.
Company overview. Jazz Pharmaceuticals plc (NASDAQ: JAZZ, commonly "Jazz Pharma") is an Ireland-domiciled, publicly traded biopharmaceutical company founded in 2003 and headquartered in Dublin, with major U.S. operations (historically Palo Alto, California). It is a standalone public company with no parent; it was incorporated in its current Irish plc form in 2012 following the merger of Jazz Pharmaceuticals, Inc. with Azur Pharma. Recent third-party profiles put headcount near 2,900, trailing-twelve-month revenue around $4.1–4.4 billion, and market capitalization in the $14–16 billion range.
Products / operations. Jazz develops and commercializes branded prescription drugs in neuroscience and oncology. Key marketed products include Xywav and Xyrem (sodium oxybate for narcolepsy/idiopathic hypersomnia), Epidiolex/Epidyolex (cannabidiol for severe epilepsies, acquired with GW Pharmaceuticals in 2021), Rylaze/Enrylaze (asparaginase for ALL/LBL), Zepzelca (small cell lung cancer), Ziihera/zanidatamab (HER2-positive biliary tract cancer), Defitelio (veno-occlusive disease), Vyxeos (AML), and Modeyso (acquired with Chimerix, 2025). It is an operating company, not a shell licensor.
Patent-litigation posture. The structured data shows a single tracked case, filed as plaintiff, with zero appearances as defendant. That profile is consistent with an operating company enforcing Orange Book formulation/method patents through Hatch-Waxman ANDA litigation rather than with a non-practicing entity; Jazz is not a patent assertion entity. Notably, the sole tracked venue is the Eastern District of New York — a venue associated with Jazz's sodium-oxybate disputes, not the plaintiff-friendly Eastern District of Texas.
Notable case / context. The tracked 2017-07-26 EDNY action corresponds to Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Ltd. v. Ascent Pharmaceuticals, Inc. (No. 2:17-cv-04439), a § 271 patent infringement suit filed after Ascent's June 2017 Paragraph IV notice on a generic Xyrem ANDA. "JPI Commercial, LLC" and "Orphan Medical" (acquired 2005) are Jazz subsidiaries/legacy entities; Orphan's earlier Xyrem marketing matter also ran through the EDNY U.S. Attorney's Office, which likely accounts for the entity labeling in the database.
A closed E.D.N.Y. action in the Jazz/JPI Commercial/Orphan Medical line involving the '106 patent per Unified Patents. The defendant was not identified in retrieved sources.